Interactome dynamics of RAF1-BRAF kinase monomers and dimers

[1]  Sylvain D. Vallet,et al.  The IntAct database: efficient access to fine-grained molecular interaction data , 2021, Nucleic Acids Res..

[2]  A. Brazma,et al.  The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences , 2021, Nucleic Acids Res..

[3]  M. Barbacid,et al.  RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression. , 2021, Cancer cell.

[4]  R. Roskoski.  Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. , 2018, Pharmacological research.

[5]  Oleksii S. Rukhlenko,et al.  Dissecting RAF Inhibitor Resistance by Structure-based Modeling Reveals Ways to Overcome Oncogenic RAS Signaling. , 2018, Cell systems.

[6]  N. Blüthgen,et al.  A compendium of ERK targets , 2017, FEBS letters.

[7]  C. Cui,et al.  Mutations in BRAF codons 594 and 596 predict good prognosis in melanoma , 2017, Oncology letters.

[8]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[9]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[10]  C. Berking,et al.  Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. , 2015, European journal of cancer.

[11]  B. Kholodenko.  Drug Resistance Resulting from Kinase Dimerization Is Rationalized by Thermodynamic Factors Describing Allosteric Inhibitor Effects. , 2015, Cell reports.

[12]  W. Kolch,et al.  On-Beads Digestion in Conjunction with Data-Dependent Mass Spectrometry: A Shortcut to Quantitative and Dynamic Interaction Proteomics , 2014, Biology.

[13]  B. Kholodenko,et al.  It takes two to tango--signalling by dimeric Raf kinases. , 2013, Molecular bioSystems.

[14]  D. Morrison,et al.  RAF Inhibitor-Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade Signaling , 2011, Current Biology.

[15]  Muffy Calder,et al.  The Mammalian MAPK/ERK Pathway Exhibits Properties of a Negative Feedback Amplifier , 2010, Science Signaling.

[16]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[17]  Chao Zhang,et al.  RAF inhibitors transactivate RAF dimers and ERK signaling in cells with wild-type BRAF , 2010, Nature.

[18]  J. Reis-Filho,et al.  Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF , 2010, Cell.

[19]  Marc Therrien,et al.  A dimerization-dependent mechanism drives RAF catalytic activation , 2009, Nature.

[20]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[21]  W. Kolch,et al.  Regulation and Role of Raf-1/B-Raf Heterodimerization , 2006, Molecular and Cellular Biology.

[22]  D. Barford,et al.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.

[23]  M. Baccarini,et al.  Raf-1 sets the threshold of Fas sensitivity by modulating Rok-α signaling , 2005, The Journal of cell biology.

[24]  Walter Kolch,et al.  Role of the Kinase MST2 in Suppression of Apoptosis by the Proto-Oncogene Product Raf-1 , 2004, Science.

[25]  Jing Chen,et al.  Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK–ERK independent mechanism , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Philip R. Cohen,et al.  Paradoxical activation of Raf by a novel Raf inhibitor. , 1999, Chemistry & biology.

[27]  OUP accepted manuscript , 2021, Nucleic Acids Research.

[28]  M. Mann,et al.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips , 2007, Nature Protocols.